Physician profile
Thomas Bridge
NPI 1932286481
$3,988.15
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,685 · 2020: $515 · 2021: $1,771 · 2023: $16.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $583.18 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $534.70 | 2019-2021 | |
| Amgen INC. | $457.76 | 2019-2021 | |
| Novo Nordisk INC | $447.42 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $329.19 | 2019-2021 | |
| Lilly USA, LLC | $316.63 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $213.75 | 2019-2021 | |
| Abbvie INC. | $202.97 | 2021 | |
| Merck Sharp & Dohme LLC | $153.45 | 2019-2021 | |
| Glaxosmithkline, LLC. | $152.88 | 2019-2021 | |
| Dexcom, INC. | $97.72 | 2021-2023 | Dexcom G6 Transmitter |
| Allergan, INC. | $83.50 | 2019-2020 | |
| Abbott Laboratories | $72.19 | 2021 | |
| Novartis Pharmaceuticals Corporation | $37.07 | 2019-2021 | |
| Astellas Pharma US INC | $32.55 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $29.50 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $29.19 | 2021 | |
| Supernus Pharmaceuticals, INC. | $27.21 | 2019 | |
| Sanofi-Aventis U.S. LLC | $25.63 | 2019 | |
| Antares Pharma, INC. | $24.68 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.91 | 2021 | |
| Sunovion Pharmaceuticals INC. | $19.04 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.91 | 2021 | |
| Ironwood Pharmaceuticals, INC | $15.14 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $15.13 | 2021 | |
| Biogen, INC. | $14.09 | 2021 | |
| Clarus Therapeutics INC. | $13.39 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.31 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Bridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.